JP2012533307A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012533307A5 JP2012533307A5 JP2012520813A JP2012520813A JP2012533307A5 JP 2012533307 A5 JP2012533307 A5 JP 2012533307A5 JP 2012520813 A JP2012520813 A JP 2012520813A JP 2012520813 A JP2012520813 A JP 2012520813A JP 2012533307 A5 JP2012533307 A5 JP 2012533307A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- antibody
- polypeptide
- template
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 239000000427 antigen Substances 0.000 claims 6
- 210000002919 epithelial cell Anatomy 0.000 claims 6
- 210000001161 mammalian embryo Anatomy 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 238000012216 screening Methods 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims 4
- 210000002950 fibroblast Anatomy 0.000 claims 4
- 210000003292 kidney cell Anatomy 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 241000282465 Canis Species 0.000 claims 2
- 241000282693 Cercopithecidae Species 0.000 claims 2
- 241000699673 Mesocricetus auratus Species 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 241000922157 Potoroidae Species 0.000 claims 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 2
- 210000002308 embryonic cell Anatomy 0.000 claims 2
- 210000004180 plasmocyte Anatomy 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 230000037432 silent mutation Effects 0.000 claims 2
- 210000005253 yeast cell Anatomy 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 241000235648 Pichia Species 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 238000005457 optimization Methods 0.000 claims 1
- 230000004845 protein aggregation Effects 0.000 claims 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27116809P | 2009-07-17 | 2009-07-17 | |
| US61/271,168 | 2009-07-17 | ||
| PCT/US2010/042302 WO2011009058A2 (en) | 2009-07-17 | 2010-07-16 | Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015094521A Division JP6193913B2 (ja) | 2009-07-17 | 2015-05-06 | 産生宿主における抗体／タンパク質パフォーマンス及び発現の同時で統合された選択及び進化 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012533307A JP2012533307A (ja) | 2012-12-27 |
| JP2012533307A5 true JP2012533307A5 (enExample) | 2013-08-29 |
| JP6193570B2 JP6193570B2 (ja) | 2017-09-13 |
Family
ID=43450243
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520813A Active JP6193570B2 (ja) | 2009-07-17 | 2010-07-16 | 産生宿主における抗体／タンパク質パフォーマンス及び発現の同時で統合された選択及び進化 |
| JP2015094521A Active JP6193913B2 (ja) | 2009-07-17 | 2015-05-06 | 産生宿主における抗体／タンパク質パフォーマンス及び発現の同時で統合された選択及び進化 |
| JP2017109593A Active JP6681131B2 (ja) | 2009-07-17 | 2017-06-02 | 産生宿主における抗体／タンパク質パフォーマンス及び発現の同時で統合された選択及び進化 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015094521A Active JP6193913B2 (ja) | 2009-07-17 | 2015-05-06 | 産生宿主における抗体／タンパク質パフォーマンス及び発現の同時で統合された選択及び進化 |
| JP2017109593A Active JP6681131B2 (ja) | 2009-07-17 | 2017-06-02 | 産生宿主における抗体／タンパク質パフォーマンス及び発現の同時で統合された選択及び進化 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US8859467B2 (enExample) |
| EP (6) | EP3406717B1 (enExample) |
| JP (3) | JP6193570B2 (enExample) |
| KR (5) | KR20190017070A (enExample) |
| CN (2) | CN102625848A (enExample) |
| AU (5) | AU2010273974B2 (enExample) |
| BR (2) | BR112012001171B1 (enExample) |
| CA (2) | CA2768247C (enExample) |
| DK (5) | DK2907873T3 (enExample) |
| ES (3) | ES2701931T3 (enExample) |
| HU (1) | HUE029328T2 (enExample) |
| IN (1) | IN2012DN00737A (enExample) |
| MX (3) | MX392642B (enExample) |
| MY (2) | MY160472A (enExample) |
| PL (2) | PL3042957T3 (enExample) |
| PT (1) | PT3042957T (enExample) |
| SG (3) | SG10201700096VA (enExample) |
| WO (1) | WO2011009058A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102625848A (zh) | 2009-07-17 | 2012-08-01 | 生物蛋白有限公司 | 在生产宿主中同时整合抗体/蛋白的性能和表达的筛选和演化的方法 |
| WO2011109726A2 (en) * | 2010-03-05 | 2011-09-09 | Bioatla Llc | Homologous multi-specific antibodies |
| ES2966088T3 (es) * | 2010-07-16 | 2024-04-18 | Bioatla Inc | Nuevos métodos de evolución de proteínas |
| AU2015242961B2 (en) * | 2010-07-16 | 2017-03-02 | Bioatla, Llc | Novel methods of protein evolution |
| CA2810668A1 (en) | 2010-09-08 | 2012-03-15 | Halozyme, Inc. | Methods for assessing and identifying or evolving conditionally active therapeutic proteins |
| WO2013067322A1 (en) * | 2011-11-03 | 2013-05-10 | Stc Biologics, Inc. | Method for determination of pharmacological properties of recombinant proteins |
| HK1221908A1 (zh) | 2013-04-29 | 2017-06-16 | Adimab, Llc | 多特异(polyspecificity)试剂，其制备方法和用途 |
| ES2819865T3 (es) | 2014-01-07 | 2021-04-19 | Bioatla Llc | Proteínas dirigidas a ortólogos |
| GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| CA2947605A1 (en) * | 2014-05-13 | 2015-11-19 | Bioatla, Llc | Conditionally active biological proteins |
| WO2016004242A1 (en) * | 2014-07-01 | 2016-01-07 | Stc Biologics, Inc. | A method for development of recombinant proteins with fingerprint like similarity to the reference product |
| EP3186284B1 (en) | 2014-08-28 | 2022-04-06 | BioAtla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
| US10513699B2 (en) | 2014-09-03 | 2019-12-24 | Bioatla, Llc | Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts |
| KR102790523B1 (ko) | 2015-02-24 | 2025-04-02 | 바이오아트라, 인코퍼레이티드 | 조건부 활성 생체 단백질 |
| KR102725051B1 (ko) * | 2015-09-23 | 2024-11-04 | 제넨테크, 인크. | 항-vegf 항체의 최적화된 변이체들 |
| US11472876B2 (en) | 2015-11-02 | 2022-10-18 | Bioatla, Inc. | Conditionally active polypeptides |
| JP7051715B2 (ja) | 2016-05-13 | 2022-04-11 | バイオアトラ、エルエルシー | 抗Ｒｏｒ２抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用 |
| EP3652209A2 (en) | 2017-07-11 | 2020-05-20 | Compass Therapeutics LLC | Agonist antibodies that bind human cd137 and uses thereof |
| WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
| US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| MX2021005594A (es) | 2018-11-13 | 2021-10-22 | Compass Therapeutics Llc | Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos. |
| EP3955960B1 (en) | 2019-04-18 | 2025-01-15 | Bristol-Myers Squibb Company | Ipilimumab variants with enhanced specificity for binding at low ph |
| EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| CN111048154B (zh) * | 2019-12-10 | 2023-06-06 | 上海药明生物技术有限公司 | 一种抗体表位作图的方法 |
| CN111462815B (zh) * | 2020-03-27 | 2023-05-02 | 上海祥耀生物科技有限责任公司 | 一种抗体库的构建方法及装置 |
| US11506060B1 (en) * | 2021-07-15 | 2022-11-22 | Honeywell International Inc. | Radial turbine rotor for gas turbine engine |
| EP4405396A2 (en) | 2021-09-20 | 2024-07-31 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| EP4522757A2 (en) | 2022-05-13 | 2025-03-19 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| TW202435912A (zh) | 2022-08-03 | 2024-09-16 | 美商航海家醫療公司 | 用於穿過血腦屏障之組合物及方法 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4957858A (en) | 1986-04-16 | 1990-09-18 | The Salk Instute For Biological Studies | Replicative RNA reporter systems |
| US4883750A (en) | 1984-12-13 | 1989-11-28 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| AU622104B2 (en) | 1987-03-11 | 1992-04-02 | Sangtec Molecular Diagnostics Ab | Method of assaying of nucleic acids, a reagent combination and kit therefore |
| CA1323293C (en) | 1987-12-11 | 1993-10-19 | Keith C. Backman | Assay using template-dependent nucleic acid probe reorganization |
| EP0359789B1 (en) | 1988-01-21 | 1993-08-04 | Genentech, Inc. | Amplification and detection of nucleic acid sequences |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| DE68911648T2 (de) | 1988-03-24 | 1994-06-23 | Univ Iowa Res Found | Katalytische hybridisierungs-systeme zum nachweis von nukleinsäuresequenzen, die auf deren aktivität als kofaktoren in katalytischen reaktionen basieren in denen eine komplementäre, markierte nukleinsäureprobe gespalten wird. |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5677149A (en) | 1992-11-24 | 1997-10-14 | G.D. Searle & Co., | Interleukin-3 (IL-3) mutant polypeptides and their recombinant production |
| US20030219752A1 (en) | 1995-12-07 | 2003-11-27 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
| US6562594B1 (en) | 1999-09-29 | 2003-05-13 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US6764835B2 (en) | 1995-12-07 | 2004-07-20 | Diversa Corporation | Saturation mutageneis in directed evolution |
| US6238884B1 (en) | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
| US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US8137906B2 (en) * | 1999-06-07 | 2012-03-20 | Sloning Biotechnology Gmbh | Method for the synthesis of DNA fragments |
| US7033781B1 (en) | 1999-09-29 | 2006-04-25 | Diversa Corporation | Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating |
| US7163681B2 (en) | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| AU2002233340B2 (en) | 2001-02-19 | 2008-05-22 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| JP2004532038A (ja) * | 2001-05-17 | 2004-10-21 | ディヴァーサ コーポレイション | 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法 |
| US7647184B2 (en) * | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
| KR20060034650A (ko) * | 2003-06-27 | 2006-04-24 | 바이오렌 인코포레이티드 | 룩-스루 돌연변이 |
| GB0520169D0 (en) * | 2005-10-04 | 2005-11-09 | Celltech R&D Ltd | Biological products |
| CA2625619A1 (en) | 2005-10-14 | 2007-04-26 | Medimmune, Inc. | Cell display of antibody libraries |
| WO2008118476A2 (en) * | 2007-03-26 | 2008-10-02 | Codon Devices, Inc. | Cell surface display, screening and production of proteins of interest |
| WO2009059235A2 (en) | 2007-11-01 | 2009-05-07 | Facet Biotech Corporation | Immunoglobulin display vectors |
| BRPI0819092A2 (pt) | 2007-11-02 | 2014-10-14 | Scripps Research Inst | Evolução direcionada usando proteínas que compreendem aminoácidos não naturais. |
| US8312249B1 (en) | 2008-10-10 | 2012-11-13 | Apple Inc. | Dynamic trampoline and structured code generation in a signed code environment |
| CN102625848A (zh) | 2009-07-17 | 2012-08-01 | 生物蛋白有限公司 | 在生产宿主中同时整合抗体/蛋白的性能和表达的筛选和演化的方法 |
| FR2957821B1 (fr) | 2010-03-24 | 2014-08-29 | Inst Francais Du Petrole | Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives |
-
2010
- 2010-07-16 CN CN2010800388394A patent/CN102625848A/zh active Pending
- 2010-07-16 DK DK15156820.1T patent/DK2907873T3/en active
- 2010-07-16 MX MX2017000699A patent/MX392642B/es unknown
- 2010-07-16 HU HUE15156820A patent/HUE029328T2/en unknown
- 2010-07-16 KR KR1020197004078A patent/KR20190017070A/ko not_active Ceased
- 2010-07-16 SG SG10201700096VA patent/SG10201700096VA/en unknown
- 2010-07-16 AU AU2010273974A patent/AU2010273974B2/en active Active
- 2010-07-16 KR KR1020217002264A patent/KR20210013294A/ko not_active Ceased
- 2010-07-16 KR KR1020217042385A patent/KR20220002712A/ko not_active Ceased
- 2010-07-16 EP EP18183032.4A patent/EP3406717B1/en active Active
- 2010-07-16 MY MYPI2012000207A patent/MY160472A/en unknown
- 2010-07-16 ES ES16196481T patent/ES2701931T3/es active Active
- 2010-07-16 MX MX2012000803A patent/MX2012000803A/es active IP Right Grant
- 2010-07-16 CN CN201611220313.3A patent/CN107090031A/zh active Pending
- 2010-07-16 PL PL16157965T patent/PL3042957T3/pl unknown
- 2010-07-16 BR BR112012001171-5A patent/BR112012001171B1/pt active IP Right Grant
- 2010-07-16 DK DK19210622.7T patent/DK3636759T3/da active
- 2010-07-16 DK DK16196481.2T patent/DK3156485T3/en active
- 2010-07-16 KR KR1020187002028A patent/KR20180010347A/ko not_active Ceased
- 2010-07-16 KR KR1020127003948A patent/KR101823872B1/ko active Active
- 2010-07-16 MX MX2015005873A patent/MX347654B/es unknown
- 2010-07-16 SG SG10201505075TA patent/SG10201505075TA/en unknown
- 2010-07-16 EP EP15156820.1A patent/EP2907873B1/en active Active
- 2010-07-16 ES ES15156820.1T patent/ES2581318T3/es active Active
- 2010-07-16 EP EP10800618.0A patent/EP2454376B1/en active Active
- 2010-07-16 CA CA2768247A patent/CA2768247C/en active Active
- 2010-07-16 JP JP2012520813A patent/JP6193570B2/ja active Active
- 2010-07-16 DK DK16157965.1T patent/DK3042957T3/en active
- 2010-07-16 PT PT161579651T patent/PT3042957T/pt unknown
- 2010-07-16 ES ES16157965.1T patent/ES2652340T3/es active Active
- 2010-07-16 WO PCT/US2010/042302 patent/WO2011009058A2/en not_active Ceased
- 2010-07-16 SG SG2012003356A patent/SG177687A1/en unknown
- 2010-07-16 US US13/384,362 patent/US8859467B2/en active Active
- 2010-07-16 BR BR122015012748-3A patent/BR122015012748A2/pt not_active Application Discontinuation
- 2010-07-16 CA CA3034484A patent/CA3034484A1/en active Pending
- 2010-07-16 EP EP19210622.7A patent/EP3636759B1/en active Active
- 2010-07-16 EP EP16196481.2A patent/EP3156485B1/en active Active
- 2010-07-16 DK DK18183032.4T patent/DK3406717T3/da active
- 2010-07-16 MY MYPI2015002586A patent/MY173037A/en unknown
- 2010-07-16 EP EP16157965.1A patent/EP3042957B1/en active Active
- 2010-07-16 PL PL15156820.1T patent/PL2907873T3/pl unknown
-
2011
- 2011-11-17 US US13/298,559 patent/US10106788B2/en active Active
-
2012
- 2012-01-25 IN IN737DEN2012 patent/IN2012DN00737A/en unknown
-
2014
- 2014-09-09 US US14/481,564 patent/US10047357B2/en active Active
-
2015
- 2015-05-06 JP JP2015094521A patent/JP6193913B2/ja active Active
- 2015-10-16 AU AU2015243076A patent/AU2015243076B2/en active Active
-
2017
- 2017-05-15 AU AU2017203243A patent/AU2017203243B2/en active Active
- 2017-06-02 JP JP2017109593A patent/JP6681131B2/ja active Active
-
2018
- 2018-08-31 US US16/118,673 patent/US10920216B2/en active Active
-
2019
- 2019-05-31 AU AU2019203813A patent/AU2019203813B2/en active Active
-
2021
- 2021-01-27 US US17/159,936 patent/US11976381B2/en active Active
- 2021-05-19 AU AU2021203220A patent/AU2021203220B2/en active Active
-
2024
- 2024-03-21 US US18/612,054 patent/US20240263354A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012533307A5 (enExample) | ||
| Mason et al. | Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning | |
| CN106605228B (zh) | 计算蛋白质设计的方法 | |
| US12441803B2 (en) | Engineered CD25 polypeptides and uses thereof | |
| CN116434844A (zh) | 用于生成蛋白质的氨基酸序列的方法和系统 | |
| Nowak et al. | Length-independent structural similarities enrich the antibody CDR canonical class model | |
| AU2011279747B2 (en) | Novel methods of protein evolution | |
| US20170066844A1 (en) | Method for mass humanization of non-human antibodies | |
| US20220081472A1 (en) | Meso-scale engineered peptides and methods of selecting | |
| Soler et al. | A consensus protocol for the in silico optimisation of antibody fragments | |
| ES2887398T3 (es) | Colección de Fv basada en combinación de proteínas y método de preparación de la misma | |
| Madsen et al. | Structural trends in antibody-antigen binding interfaces: a computational analysis of 1833 experimentally determined 3D structures | |
| Kuroda et al. | Structural classification of CDR-H3 in single-domain VHH antibodies | |
| Arslan et al. | Protein engineering approaches for antibody fragments: directed evolution and rational design approaches | |
| CN115116543B (zh) | 抗原抗体结合位点确定方法、装置、设备和存储介质 | |
| CN109415441A (zh) | 抗体及其制备方法 | |
| Sivasubramanian et al. | Modeling the structure of mAb 14B7 bound to the anthrax protective antigen | |
| Jian et al. | Effective binding to protein antigens by antibodies from antibody libraries designed with enhanced protein recognition propensities | |
| CN104530228B (zh) | 一种人源抗乙肝病毒表面抗体及其制备方法和应用 | |
| Frisby et al. | Identifying promising sequences for protein engineering using a deep transformer protein language model | |
| JP6665274B2 (ja) | 標的分子に結合するポリペプチドの決定方法及び決定システム | |
| Rockberg et al. | Prediction of antibody response using recombinant human protein fragments as antigen | |
| Tennenhouse et al. | Energy-guided combinatorial co-optimization of antibody affinity and stability | |
| Fischman et al. | Redirecting an anti-IL-1β antibody to bind a new, unrelated and computationally predicted epitope on hIL-17A | |
| Paul | Modelling Sequence and Structure Towards Functional Protein Design |